A First-in-human Study Using BDC-1001 in Advanced HER2-Expressing Solid Tumors

A First-in-human Study Using BDC-1001 in Advanced HER2-Expressing Solid Tumors
Conditions:   Neoplasm, Metastatic;   Neoplasm, Breast;   Neoplasm, Gastric
Interventions:   Drug: BDC-1001;   Drug: Pembrolizumab
Sponsor:   Bolt Biotherapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 28, 2020Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments